Hostname: page-component-745bb68f8f-kw2vx Total loading time: 0 Render date: 2025-01-11T07:09:14.606Z Has data issue: false hasContentIssue false
  • English
  • Français

Do Children and Adolescents Have Differential Response Rates in Placebo-Controlled Trials of Fluoxetine?

Published online by Cambridge University Press:  07 November 2014

Taryn L. Mayes ,
Rongrong Tao ,
Jeanne W. Rintelmann ,
Thomas Carmody ,
Carroll W. Hughes ,
Beth D. Kennard ,
Sunita M. Stewart  and
Graham J. Emslie
Get access Rights & Permissions [Opens in a new window]

Abstract

Objective:

Recent acute efficacy trials of antidepressants in youth have suggested that high placebo-response rates in children (<12 years of age) indicate that children may be more responsive to non-specific treatment interventions. Yet, these studies generally have not presented age-specific outcome data. The objective of this study was to compare the efficacy outcomes for children (<12 years of age) and adolescents (≥12 years of age) using the combined data from two previously published double-blind, placebo-controlled trials of fluoxetine.

Methods:

Children (<12 years of age) and adolescents (≥12 years of age) with major depressive disorder were randomized to fluoxetine or placebo for 8–9 weeks of treatment. Outcome was assessed using the Children's Depression Rating Scale-Revised (CDRS-R) and Clinical Global Impressions scale.

Results:

Random regression of the CDRS-R showed a treatment group by age group interaction (F1,338=4.10, P=.044), indicating that the treatment effect was significantly more pronounced in children than adolescents. Within children, response at exit to fluoxetine was significantly better than placebo (56.9% vs 33.3%; P=.009). Adolescent response rates at exit were not significantly different between the groups (51.1% vs 38.6%; P=.128). Remission rates were low for both groups.

Conclusion:

In the combined fluoxetine trials, drug-placebo difference was greater in children compared with adolescents. Contrary to expectations, the placebo-response rate was lower in the children than the adolescents.

Type
Original Research
Information
CNS Spectrums , Volume 12 , Issue 2 , February 2007 , pp. 147 - 154
Copyright
Copyright © Cambridge University Press 2007

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

REFERENCES

1.Birmaher, B, Ryan, ND, Williamson, DE, Brent, DA, Kaufman, J. Childhood and adolescent depression: a review of the past 10 years. Part II. J Am Acad Child Adolesc Psychiatry. 1996;35:1575–1583.CrossRefGoogle ScholarPubMed
2.Kovacs, M. Presentation and course of major depressive disorder during childhood and later years of the life span. J Am Acad Child Adolesc Psychiatry. 1996;35:705–715.CrossRefGoogle ScholarPubMed
3.Hazell, P, O'Connell, D, Heathcote, D, Henry, D. Tricyclic drugs for depression in children and adolescents. Cochrane Database Syst Rev. 2002;(2):CD002317.Google ScholarPubMed
4.Emslie, GJ, Rush, AJ, Weinberg, WA, et al. Double-blind placebo controlled study of fluoxetine in depressed children and adolescents. Arch Gen Psychiatry. 1997;54:1031–1037.CrossRefGoogle ScholarPubMed
5.Emslie, GJ, Heiligenstein, JH, Wagner, KD, et al. Fluoxetine for acute treatment of depression in children and adolescents: a placebo-controlled, randomized clinical trial. J Am Acad Child Adolesc Psychiatry. 2002;41:1205–1215.CrossRefGoogle ScholarPubMed
6.Keller, MB, Ryan, ND, Strober, M, et al. Efficacy of paroxetine in the treatment of adolescent major depression: A randomized, controlled trial. J Am Acad Child Adolesc Psychiatry. 2001;40:762–772.CrossRefGoogle ScholarPubMed
7.Treatment for Adolescents with Depression Study Team. Fluoxetine, cognitive-behavioral therapy, and their combination for adolescents with depression: Treatment for Adolescents With Depression Study (TADS) randomized controlled trial. JAMA. 2004;292:807–820.CrossRefGoogle Scholar
8.Wagner, KD, Ambrosini, PJ, Rynn, M, et al. Efficacy of sertraline in the treatment of children and adolescents with major depressive disorder. JAMA. 2003;290:1033–1041.CrossRefGoogle ScholarPubMed
9.Wagner, KD, Robb, AS, Findling, RL, Jin, J, Gutierrez, MM, Heydorn, WE. A randomized, placebo-controlled trial of citalopram for the treatment of major depression in children and adolescents. Am J Psychiatry. 2004;161:1079–1083.CrossRefGoogle ScholarPubMed
10.Emslie, GJ, Wagner, KD, Kutcher, S, et al. Paroxetine treatment in children and adolescents with major depressive disorder: a randomized, multicenter, double-blind, placebo-controlled trial. J Am Acad Child Adolesc Psychiatry. 2006;45:709–719.CrossRefGoogle ScholarPubMed
11.Wagner, KD, Jonas, J, Findling, RL, Ventura, D, Saikali, K. A double-blind, randomized, placebo-controlled trial of escitalopram in the treatment of pediatric depression. J Am Acad Child Adolesc Psychiatry. 2006;45:280–288.CrossRefGoogle ScholarPubMed
12.Emslie, GJ, Findling, RL, Yeung, PP, Kunz, NR, Li, Y. Efficacy and safety of venlafaxine ER in the treatment of pediatric major depressive disorder. J Am Acad Child Adolesc Psychiatry. In press.Google Scholar
13.Poznanski, E, Mokros, H. Children's Depression Rating Scale-Revised (CDRS-R). Los Angeles, Calif: WPS; 1996.Google Scholar
14.Guo, Y, Nilsson, ME, Heiligenstein, J, Wilson, MG, Emslie, GJ. An exploratory factor analysis of the Children's Depression Rating Scale–Revised. J Child Adolesc Psychopharmacol. 2006;16:482–491.CrossRefGoogle ScholarPubMed
15.Guy, W. ECDEU Assessment Manual for Psychopharmacology. Washington, DC: US Department of Health, Education and Welfare; 1976.Google Scholar
16.Kraemer, HC, Wilson, GT, Fairburn, CG, Agras, WS. Mediators and moderators of treatment effects in randomized clinical trials. Arch Gen Psychiatry. 2002;59:877–883.CrossRefGoogle ScholarPubMed
17.DeVeaugh-Geiss, J, March, J, Shapiro, M, et al. Child and adolescent psychopharmacology in the new millennium: a workshop for academia, industry, and government. J Am Acad Child Adolesc Psychiatry. 2006;45:261–270.CrossRefGoogle ScholarPubMed
18.Cheung, AH, Emslie, GJ, Mayes, TL. Review of the efficacy and safety of antidepressants in youth depression. J Child Psychol Psychiatry. 2005;46:735–754.CrossRefGoogle ScholarPubMed